ERBB2 and breast cancer: Even in the setting that it might not be an adequate surrogate of overall survival in HR+HER2- patients [14], recent real-world evidence has identified that the overall survival of the pCR population of Her2 positive, triple negative, and luminal B breast cancer is similar.